搜尋結果
和鉑醫藥與阿斯利康訂立新型腫瘤靶向療法許可及選擇權協議
infocast via Yahoo財經香港· 7 日前和鉑醫藥(02142)宣布,公司全資附屬諾納生物(蘇州),已就將用於創建腫瘤靶向療法的臨床前單克隆抗體,與阿斯利康訂立許可及選擇權協議。根據協議,諾納生 ...
Manga mania: Hong Kong Doraemon show to bring 135 large-scale models, short film
South China Morning Post· 5 日前Jitsuko Katsumata, a daughter of the late manga master, told the Post during an interview at ...
After 20 Years, ‘Paper Mario: The Thousand Year Door’ Reopens On Nintendo Switch
Forbes· 7 日前If you own a Nintendo Switch and have been hankering for some quasi-2D turn-based RPG action ...
Hong Kong’s immigration office in Tseung Kwan O to feature marriage registry
South China Morning Post· 13 小時前The other five locations are at Cotton Tree Drive and City Hall in Central, and in Tsim Sha ...
Two Legends On Love, Laughter And A Las Vegas Residency
Forbes· 5 日前Dynamic duos are nothing new for Las Vegas. What’s special about this latest power pairing, ...
How To Get From New York City To The Hamptons
Forbes· 18 小時前Beach season has finally touched down on New York, and that means plenty of trips to and from ...
Rents on global luxury homes cool in first quarter as Singapore drags market
South China Morning Post· 2 日前The latest report showed 12 of the 15 cities registering positive rent growth, led by Sydney ...
即時新聞 - 重要通告 - 和鉑醫藥與阿斯利康訂立新型腫瘤靶向療法許可 - 信報網站 hkej.com
信報· 7 日前和鉑醫藥(02142)公布,旗下全資附屬公司諾納生物(蘇州),已就將用於創建腫瘤靶向療法的臨床前單克隆抗 ...
Letter | 10 big-picture ideas to get Hong Kong tourism on the right track
South China Morning Post· 20 小時前Develop a spa hotel on Kau Sai Chau, near the golf course, with high-speed boat connections to ...
和鉑醫藥(02142)與阿斯利康就腫瘤靶向療法訂許可協議 升19%
infocast via Yahoo財經香港· 7 日前和鉑醫藥(02142)公布,全資附屬諾納生物(蘇州),已就將用於創建腫瘤靶向療法的臨床前單克隆抗體與阿斯利康阿斯利康訂立許可及選擇權協議,根據協議,諾納生 ...